Case Report: Post-transplant Lymphoproliferative Disorder As a Serious Complication of Vascularized Composite Allotransplantation

Overview

Journal Front Transplant

Specialty General Surgery

Date 2024 Jul 12

PMID 38993757

Authors

Alessandra Zaccardelli

Fabienne M Lucas

Ann S LaCasce

Anil K Chandraker

Jamil R Azzi

Simon G Talbot

Affiliations

Soon will be listed here.

Abstract

Vascularized composite allotransplantation (VCA) is an emerging field in transplant surgery. Despite overall positive outcomes, VCA confers risk for multiple complications related to the procedure and subsequent immunosuppression. Post-transplant lymphoproliferative disorder (PTLD) is a heterogeneous group of lymphoproliferative disorders occurring after solid organ and hematopoietic stem cell transplant. A patient with PTLD after bilateral upper extremity transplantation is presented as well as a review of all known cases of PTLD after VCA, with a focus on the unique epidemiology, presentation, and treatment in this population.

References

Petruzzo P, Kanitakis J, Testelin S, Pialat J, Buron F, Badet L . Clinicopathological Findings of Chronic Rejection in a Face Grafted Patient. Transplantation. 2015; 99(12):2644-50. DOI: 10.1097/TP.0000000000000765. View

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

Asleh R, Vucicevic D, Petterson T, Kremers W, Pereira N, Daly R . Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study. J Clin Med. 2022; 11(2). PMC: 8779206. DOI: 10.3390/jcm11020322. View

Campo E, Jaffe E, Cook J, Quintanilla-Martinez L, Swerdlow S, Anderson K . The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140(11):1229-1253. PMC: 9479027. DOI: 10.1182/blood.2022015851. View

Dharnidharka V, Sullivan E, Stablein D, Tejani A, Harmon W . Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation. 2001; 71(8):1065-8. DOI: 10.1097/00007890-200104270-00010. View

Stead T, Brydges H, Laspro M, Onuh O, Chaya B, Rabbani P . Minimally and Non-invasive Approaches to Rejection Identification in Vascularized Composite Allotransplantation. Transplant Rev (Orlando). 2023; 37(4):100790. DOI: 10.1016/j.trre.2023.100790. View

Stern M, Opelz G, Dohler B, Hess C . Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood. 2010; 115(19):3960-5. DOI: 10.1182/blood-2009-10-250134. View

Trappe R, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha J . Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. J Clin Oncol. 2016; 35(5):536-543. DOI: 10.1200/JCO.2016.69.3564. View

Singh M, Oser M, Zinser J, Sisk G, Carty M, Sampson C . Psychosocial Outcomes after Bilateral Hand Transplantation. Plast Reconstr Surg Glob Open. 2015; 3(10):e533. PMC: 4634170. DOI: 10.1097/GOX.0000000000000520. View

10.

Zaffiri L, Chambers E . Screening and Management of PTLD. Transplantation. 2023; 107(11):2316-2328. DOI: 10.1097/TP.0000000000004577. View

11.

Quintanilla-Martinez L, Swerdlow S, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe E . New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2022; 482(1):227-244. PMC: 9852222. DOI: 10.1007/s00428-022-03414-4. View

12.

Opelz G, Dohler B . Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004; 4(2):222-30. DOI: 10.1046/j.1600-6143.2003.00325.x. View

13.

Atallah-Yunes S, Salman O, Robertson M . Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies. Br J Haematol. 2023; 201(3):383-395. DOI: 10.1111/bjh.18763. View

14.

Al-Mansour Z, Nelson B, Evens A . Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013; 8(3):173-83. PMC: 4831913. DOI: 10.1007/s11899-013-0162-5. View

15.

VanBuskirk A, Malik V, Xia D, Pelletier R . A gene polymorphism associated with posttransplant lymphoproliferative disorder. Transplant Proc. 2001; 33(1-2):1834. DOI: 10.1016/s0041-1345(00)02700-7. View

16.

Singh M, Sisk G, Carty M, Sampson C, Blazar P, Dyer G . Functional Outcomes after Bilateral Hand Transplantation: A 3.5-Year Comprehensive Follow-Up. Plast Reconstr Surg. 2015; 137(1):185-189. DOI: 10.1097/PRS.0000000000001872. View

17.

Bishnoi R, Minish J, Franke A, Skelton 4th W, Shah C, Wang Y . Single-institution Retrospective Analysis of Prognostic Factors Influencing Very Late-onset Post-transplant Lymphoproliferative Disorder. Cureus. 2020; 12(2):e6912. PMC: 7061783. DOI: 10.7759/cureus.6912. View

18.

Reshef R, Luskin M, Kamoun M, Vardhanabhuti S, Tomaszewski J, Stadtmauer E . Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant. 2011; 11(4):817-25. PMC: 3072270. DOI: 10.1111/j.1600-6143.2011.03454.x. View

19.

Jagadeesh D, Woda B, Draper J, Evens A . Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol. 2012; 13(1):122-36. DOI: 10.1007/s11864-011-0177-x. View

20.

Shores J, Malek V, Lee W, Brandacher G . Outcomes after hand and upper extremity transplantation. J Mater Sci Mater Med. 2017; 28(5):72. DOI: 10.1007/s10856-017-5880-0. View